Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176930 | 0.84 | TYMP (0.48) | HPGDKMT2AMEN1DAOCYP1A2 | |
| SCHEMBL12169429 | 0.84 | HPGD (0.59) | HPGDMAPK1 | |
| SCHEMBL7839293 | 0.81 | TYMP (0.52) | HPGDKMT2AMEN1DAOTYMP | |
| SCHEMBL4172004 | 0.80 | HPGD (0.44) | HPGDKMT2AMEN1DAOCYP1A2 | |
| SCHEMBL24495513 | 0.80 | DAO (0.72) | HPGDKMT2AMEN1DAOMAPK1 | |
| SCHEMBL1717207 | 0.80 | MEN1 (0.78) | HPGDKMT2AMEN1DAOCYP1A2 | |
| SCHEMBL5115615 | 0.80 | HPGD (0.67) | HPGDKMT2AMEN1DAOCYP1A2 | |
| SCHEMBL3996660 | 0.80 | HPGD (1.00) | HPGDMAPK1TK1 | |
| SCHEMBL4163074 | 0.79 | L3MBTL1 (0.50) | HPGDDAO | |
| SCHEMBL7821405 | 0.79 | HPGD (0.69) | HPGDKMT2AMEN1DAOMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113387895-B | Synthesis method of nitric acid catalyzed 5-iodopyrimidine derivative | 新乡学院 | 2023-03-14 | — | — | CN | disclosed |
| CN-113387895-A | Synthesis method of nitric acid catalyzed 5-iodopyrimidine derivative | 新乡学院 | 2021-09-14 | — | — | CN | disclosed |
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| WO-2007122634-A2 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006070292-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1385831-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-02-04 | — | — | EP | disclosed |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY (CA) | 2003-08-14 | — | — | US | disclosed |
| WO-2002083651-A2 | PYRIMIDINE COMPOUNDS AS ANTI-ICTOGENIC AND/OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | TK1, LCK, FYN | HPGD 1010/4885KMT2A 2499/4885MEN1 2840/4885 |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | NUDT1, DPYD, TYMP | HPGD 459/4885KMT2A 1914/4885MEN1 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.